Here's your US drug review and approval news for the week in brief: Sandoz Inc. finally can take its turn to celebrate, as the Novartis AG unit scored a long-awaited approval for its biosimilar of Amgen Inc.'s Neulasta (pegfilgrastim).
The Center for Drug Evaluation and Research (CDER) also cleared two more novel agents last week, granting approvals to